Allied Market Research
Loading...
0
Upcoming Allied Market Research
2021
Leukocytoclastic Vasculitis Market

Leukocytoclastic Vasculitis Market by Drug Type (Biosimilars, Corticosteroids, Immunosuppressive Agent, NSAIDs, Colchicine, and Sulfones) and Indication (Infections, Malignancy, Connective Tissue Disease, and Autoimmune Disease): Global Opportunity Analysis and Industry Forecast, 2021–2030

A14014
Pages: NA
Dec 2021 | 36 Views
   
Author(s) : NA
Tables: NA
Charts: NA
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Leukocytoclastic Vasculitis Market

Request Now !

Leukocytoclastic vasculitis (LCV) commonly occurs with palpable purpura on the lower extremities and observed followed by underlying systemic autoimmune diseases, chronic infections, and malignancies. LCV is mostly triggered by Staphylococcus aureus, Mycobacterium, Neisseria, Chlamydia.

Depending on the symptoms and cause treatment varies. Treating the underlying infection by eliminating irritating agent such as drugs will remove the symptoms of leukocytoclastic vasculitis disease. In the treatment of the leukocytoclastic vasculitis, the medications such as prednisone, pentoxifylline, cyclophosphamide, and azathioprine have proven to be effective.

Market Scope and Structure Analysis

Report Metric

Details

  Market Size Available for Years

  2020–2030

  Base Year Considered

  2020

  Forecast Period

  2021–2030

  Forecast Unit

  Value (USD)

  Segments Covered

  Drug Type, Indication, and Region

  Regions Covered

  North America, Europe, Asia-Pacific, LAMEA

  Companies Covered

Hoffman La Roche Ltd., GlaxoSmithKline Plc, Baxter International, Eli Lilly & Company, AstraZeneca, Teva Pharmaceuticals, Novo Nordisk A/S, Daiichi Sankyo, Bristol Myers Squibb Company, ChemoCentryx, Celgene Corporation, Merck & Co, Goodwin Procter LLP, Celltrion Healthcare, Intract Pharma., Bristol Myers Squibb

 

COVID-19 Impact analysis

  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global leukocytoclastic vasculitis market.

Top Impacting Factors
Increase in cases of blood vessel inflammatory diseases and rising prevalence of chronic, metabolic, and circulatory diseases such as peripheral arterial disease (PAD) have increased demand for minimally invasive procedures for the treatment of leukocytoclastic vasculitis. In addition, increase in concerns among consumers about health and increase in healthcare expenditure are the factors that drive the growth of leukocytoclastic vasculitis market
Additionally, investment in research and development programs, increase in healthcare infrastructure U.S. FDA approval for newer biosimilars in combination with other drugs, and increase in alternative biosimilars in the market with large-scale pharmaceutical retailers promoting biosimilars to mainstream consumers are expected to expand the market.
However, lack of awareness among the elder population about leukocytoclastic vasculitis and related treatment, the strict regulatory approval process, and high cost related with biosimilars for the treatment act as hindrance for the growth of the global leukocytoclastic vasculitis market.
Conversely, high cost of biosimilars motivates the pharmaceutical companies to invest in research and development to find cost-effective alternative biosimilars with positive outcomes for the treatment of leukocytoclastic vasculitis.
Market Trends
New product launches to flourish the market

  • Key players are acquiring prime strategies such as mergers and acquisitions, strategic collaborations,  product launches, and geographical expansions in the global leukocytoclastic vasculitis market. 
  • In 2020, Amgen’s RIABNI (rituximab-arrx) received U.S. Food and Drug Administration (FDA) approval as a biosimilar to Rituxan (rituximab) for the treatment of adult patients having granulomatosis polyangiitis (GPA) as well as microscopic polyangiitis (MPA).
  • In September 2019, Roche’s Rituxan (rituximab) obtained the U.S. Food and Drug Administration approval for the treatment of granulomatosis with microscopic polyangiitis (MPA) and polyangiitis (GPA) in pediatric patients with age more than 2 years. 
  • Likewise, Bristol-Myers Squibb Company acquired the U.S. Food and Drug Administration (FDA) approval for Rituxan (rituximab) to update the label to involve information on follow-up treatment of adult patients with GPA and MPA.
  • Many of the leading manufacturers are investing in research and development to develop new therapeutic products with additional clinical outcomes and launching biosimilar of the existing drugs for the treatment of leukocytoclastic vasculitis in lower to middle-income countries to attain a competitive advantage.
  • In 2020, Teva pharmaceuticals Inc. signed an exclusive collaboration agreement with Celltrion Healthcare to launched TRUXIMA (rituximab-abbs) Injection, in the U.S. for GPA and MPA in adult patients in combination with glucocorticoids. Celltrion entered into a partnership agreement with Intract Pharma to develop the World’s first oral infliximab and they launched REMSIMA SC (infliximab) in Europe for GPA and MPA in adult patients.

Key Segments Covered

Segment

Subsegment

  Drug Type

  • Biosimilars
  • Rituximab
  • Infliximab
  • Adalimumab
  • Corticosteroids
  • Immunosuppressive Agent
  • NSAIDs
  • Colchicine
  • Sulfones
  • Dapsone

  Indication

  • Infections
  • Malignancy
  • Connective Tissue Disease
  • Autoimmune Disease

 Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

 

Key Benefits of the Report

  • This study presents the analytical depiction of the leukocytoclastic vasculitis industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the leukocytoclastic vasculitis market share.
  • The current market is quantitatively analyzed from 2020 to 2030 to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed leukocytoclastic vasculitis market analysis depending on competitive intensity and how the competition will take shape in coming years

Questions Answered in the Leukocytoclastic Vasculitis Report

  • Who are the leading market players active in the leukocytoclastic vasculitis market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is " leukocytoclastic vasculitis "?
  • What is " leukocytoclastic vasculitis " market prediction in the future?
  • Who are the leading global players in the " leukocytoclastic vasculitis " market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the " leukocytoclastic vasculitis " market report?
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Start reading ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
Allied Market Research Allied Market Research Allied Market Research

Access from any device, anywhere

Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

REQUEST TOC/SAMPLE

OR

Purchase Full Report of
Leukocytoclastic Vasculitis Market

Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $5,192
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,995  $8,996
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers